Scutellarin combined with lidocaine exerts antineoplastic effect in human glioma associated with repression of epidermal growth factor receptor signaling

• DOI: 10.1371/journal.pone.0318031
• Publication Date: 2025-01-31
• Authors: Xiuying He; Yinghong Yang; Yiqing Zheng; Qingjie Xia; Haipeng Yu; Xiaoming Zhao; Ting‐Hua Wang
• Keywords: Science; Q; R; Medicine; Research Article

Glioma is the most common primary intracranial tumors. Although great achievements have been made in treatment, efficacy still unsatisfactory, which imposes a hefty burden on patients and society. Therefore, exploration of new effective anti-glioma drugs urgent. Human glioma cell lines U251 LN229 were included study. Cell proliferation was detected by counting kit-8 (CCK8), plate clone formation assay, EdU incorporation assay xCELLigence real-time analyzer. apoptosis evaluated TUNEL flow cytometry. Then, transwell used for assessing migration. Moreover, tumor xenograft model established to examine effect scutellarin (SCU) lidocaine growth vivo. Lastly, western blot performed detect protein level epidermal factor receptor (EGFR). In present study, we found that SCU suppressed migration, induced human lines, including cells, dose-dependent manner vitro. combination further restrained migration ability while their Additionally, also inhibited vivo, better. Above all, toxicity its with low normal astrocytes neurons. Mechanistically, cells partially associated repression EGFR signaling. Scutellarin exerted synergistic suppressing inducing partly